Twelve Kurzweil longevity predictions from 2005, scored against a 2025 mouse rejuvenation trial, a 2026 first-in-human reprogramming IND, 25 senolytic clinical trials, and one bankruptcy.
Kurzweil in 2005 picked torcetrapib and Apo-A-I Milano as his evidence that atherosclerosis reversal was imminent. Both failed. The drugs that actually regressed plaque came from mechanisms his book did not name.
Seven 2005 predictions about replacement organs, therapeutic cloning, and bloodstream nanobots — graded against 2026 reality.